Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma
| Status: | Completed |
|---|---|
| Conditions: | Asthma |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 19 - 20 |
| Updated: | 10/13/2017 |
| Start Date: | April 2016 |
| End Date: | June 2017 |
Advisory Committee for Immunization Practices (ACIP) from the Centers for Disease Control
(CDC) recommends that children (6-18 years) and adults (≥19 years old) with chronic lung
condition such as asthma or cigarette smoking be vaccinated with Pneumococcal vaccine
(PPSV23). The purpose of this study is to increase awareness of vaccination to late
adolescents with asthma and smokers (social aspect of study), and to recommend vaccination
(which is the clinical aspect). Individuals who agree to receiving vaccine will be enrolled
in research to determine whether late adolescents with and without asthma (smokers) have
distinctive pneumococcal vaccine response patterns and whether such patterns are associated
with subsequent variance in asthma outcomes.
(CDC) recommends that children (6-18 years) and adults (≥19 years old) with chronic lung
condition such as asthma or cigarette smoking be vaccinated with Pneumococcal vaccine
(PPSV23). The purpose of this study is to increase awareness of vaccination to late
adolescents with asthma and smokers (social aspect of study), and to recommend vaccination
(which is the clinical aspect). Individuals who agree to receiving vaccine will be enrolled
in research to determine whether late adolescents with and without asthma (smokers) have
distinctive pneumococcal vaccine response patterns and whether such patterns are associated
with subsequent variance in asthma outcomes.
Inclusion Criteria:
- Reside in Olmsted County, Minnesota (defined by Olmsted County address in medical
record within one year prior to last follow-up date as of data abstraction)
- Receive medical care from Mayo Clinic clinical practice
- Signed research authorization for using medical record for research
Exclusion Criteria:
- Diagnosis of an immunodeficiency (primary and secondary)
- Previous or current diagnosis of a Rheumatological disorders (Rheumatoid arthritis,
Lupus, Sjögren, and vasculitis), cancer (chronic lymphocytic leukemia, non-Hodgkin
lymphoma, and B-cell malignancy), diabetes, active infection (pneumonia, otitis media,
HIV, and EBV), other chronic diseases (multiple sclerosis, etc), renal disease such
nephritic syndrome, and protein losing enteropathy
- Current or previous use (within the last 6 months) of systemic corticosteroids, and
other immunosuppressive agents (cyclosporin, methotrexate, and mycophenolic acid)
- Vaccination of PPSV-23 (receiving childhood pneumococcal vaccination during infancy is
eligible for this study)
- Pregnancy
Enrollment will be delayed 2 weeks for those subjects that can be included but have upper
respiratory infection or viral illness to allow for natural resolution.
We found this trial at
1
site
Rochester, Minnesota 55905
Principal Investigator: Rohit D Divekar, MBBS, PhD
Phone: 507-255-3360
Click here to add this to my saved trials
